Literature DB >> 8102300

Neuroleptic malignant syndrome and clozapine.

S Reddig1, A M Minnema, R Tandon.   

Abstract

Clozapine is an atypical neuroleptic drug that was initially thought not to cause neuroleptic malignant syndrome (NMS). We report a case of NMS associated with clozapine as a single agent that developed in a patient with no prior history of NMS. In contrast to other reported cases of NMS with clozapine monotherapy in which rigidity was reported to be absent, our patient had classic NMS with lead-pipe rigidity. NMS should be included in the differential diagnosis of a febrile patient with a history of any neuroleptic treatment, including clozapine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102300     DOI: 10.3109/10401239309148920

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  4 in total

1.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

2.  Risk factors in neuroleptic malignant syndrome.

Authors:  Vinay Gupta; Rakesh Magon; B P Mishra; G B S Sidhu; Ranjiv Mahajan
Journal:  Indian J Psychiatry       Date:  2003-01       Impact factor: 1.759

3.  Neuroleptic malignant syndrome and lithium carbonate.

Authors:  S Fava; A C Galizia
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

4.  Unassisted smothering in a pillow.

Authors:  Andreas Schmeling; Tony Fracasso; Fritz Pragst; Michael Tsokos; Ingo Wirth
Journal:  Int J Legal Med       Date:  2009-07-21       Impact factor: 2.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.